Reports of PML in Tysabri users

Dublin/Boston: Elan, along with its product partner Biogen, has reported another increase in instances of rare brain disease PML among users of its headline multiple sclerosis/Crohn’s disease treatment Tysabri.

Reports of PML in Tysabri users
Thu, 16 Sep, 2010 - 01:00

The monthly update showed two more cases in August, bringing total PML cases to 68.

More in this section

empty J1 USA visa for man US visa crackdown is an assault on students' rights
Sad boy standing alone in the hallway Derval McDonagh: We cannot say what happened to Grace will not happen again 
AI chat technology, Businessman use smartphone with virtual screen of AI chatbot communicate and answer questions. Artificial in Agentic opportunity for Irish business: The time to act is now
CourtsPlace: TysabriPlace: DublinPlace: BostonOrganisation: ElanOrganisation: BiogenOrganisation: Tysabri
<p>In the first eight months of the year, 116,099 new cars were registered, a 3.4% increase, of which 20,656 were electric cars representing a 37% year-on-year increase. File picture</p>

Electric car sales surge by 70% in Ireland, but Tesla's decline continues

READ NOW

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Latest

Business

Push Notifications

By clicking on sign up you will be the first to know about a selection of business content on this browser. Please note if you are unable to sign up via your mobile web browser, download and sign up for mobile push notifications via our FREE news app.

Sign Up
IE logo
Devices


UNLIMITED ACCESS TO THE IRISH EXAMINER FOR TEAMS AND ORGANISATIONS
FIND OUT MORE

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Fergus Finlay
Fergus Finlay

Analysis

Lunchtime News

Newsletter

Keep up with stories of the day with our lunchtime news wrap and important breaking news alerts.

Most Read

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited